• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Barlow Jane F

    5/18/22 8:12:43 PM ET
    $CFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CFRX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Barlow Jane F

    (Last) (First) (Middle)
    C/O CONTRAFECT CORPORATION
    28 WELLS AVE, 3RD FLOOR

    (Street)
    YONKERS NY 10701

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CONTRAFECT Corp [ CFRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/17/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Options (Right to Buy) $3.35 05/17/2022 A 42,000 (1) 05/17/2032 Common Stock 42,000 $3.35 42,000 D
    Explanation of Responses:
    1. Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date.
    Remarks:
    /s/ Michael Messinger, attorney-in-fact for Jane Barlow 05/18/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CFRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CFRX

    DatePrice TargetRatingAnalyst
    7/14/2022$1.00Outperform → Mkt Perform
    SVB Leerink
    7/14/2022$15.00 → $1.00Overweight → Neutral
    Cantor Fitzgerald
    2/16/2022$14.00 → $9.00Outperform
    SVB Leerink
    2/2/2022$6.50Speculative Buy → Buy
    WBB Securities
    9/9/2021$14.00Outperform
    SVB Leerink
    More analyst ratings

    $CFRX
    SEC Filings

    See more
    • SEC Form 25-NSE filed by ContraFect Corporation

      25-NSE - CONTRAFECT Corp (0001478069) (Subject)

      12/27/23 9:01:56 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ContraFect Corporation filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update

      8-K - CONTRAFECT Corp (0001478069) (Filer)

      11/15/23 4:41:00 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by ContraFect Corporation

      10-Q - CONTRAFECT Corp (0001478069) (Filer)

      11/14/23 4:00:30 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study

      YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that the U.S. Food and Drug Administration (FDA) has notified the company that it has completed the safety review of its Investigational New Drug (IND) application for CF-370 for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), and concluded that the company may proceed with its Phase 1 clinical study. This milestone is significant for ContraFect and historic in the field of

      10/16/23 7:30:00 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

      YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Jane Ambler, Ph.D., the Company's Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston, MA from September 19-22, 2023. Dr. Ambler's presentation will review the current standards for antimicrobial susceptibility testing (AST) for the determination of antibacterial activity of therap

      9/19/23 8:30:00 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370

      YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023. The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). HABP/VABP are serious, potentially life-threatening infections that are associated with h

      9/18/23 7:30:00 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ContraFect Corporation (Amendment)

      SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)

      2/14/24 2:24:05 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ContraFect Corporation

      SC 13G - CONTRAFECT Corp (0001478069) (Subject)

      2/14/23 12:22:09 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ContraFect Corporation (Amendment)

      SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)

      9/9/22 11:03:32 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ContraFect downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded ContraFect from Outperform to Mkt Perform and set a new price target of $1.00

      7/14/22 7:16:02 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ContraFect downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded ContraFect from Overweight to Neutral and set a new price target of $1.00 from $15.00 previously

      7/14/22 7:15:41 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on ContraFect with a new price target

      SVB Leerink reiterated coverage of ContraFect with a rating of Outperform and set a new price target of $9.00 from $14.00 previously

      2/16/22 5:18:49 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Messinger Michael

      4 - CONTRAFECT Corp (0001478069) (Issuer)

      2/16/23 8:09:36 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Barlow Jane F

      4 - CONTRAFECT Corp (0001478069) (Issuer)

      5/18/22 8:12:43 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sucoff Cary

      4 - CONTRAFECT Corp (0001478069) (Issuer)

      5/18/22 8:03:32 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

      Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is

      5/23/22 8:00:00 AM ET
      $CFRX
      $CLGN
      $ENLV
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • Imvax Further Strengthens Leadership Team with Appointment of Josh Muntner as Chief Financial Officer

      Imvax, a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of Josh Muntner as the company's chief financial officer effective August 31, 2021. "We are proud to further bolster our leadership team with the appointment of Josh, who brings to Imvax significant expertise in areas of capital markets and fundraising which will be instrumental to our continued trajectory of growth," said John P. Furey, CEO of Imvax. "I also want to express my profound thanks to Art Howe, co-founder of Imvax and outgoing CFO, for his tireless efforts building the company over the years. We are at a point of exciting momentum as we progress

      8/9/21 8:00:00 AM ET
      $CFRX
      $MESO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development

      YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Gary Woodnutt, Ph.D. has been appointed as Senior Vice President of Translational Sciences and Preclinical Development. Dr. Woodnutt will oversee the scientific strategy for the Company's early stage assets and the performance of the extensive translational programs required to proceed into clinical trials. He will have a pivotal role i

      6/17/21 7:31:00 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care